Production of interleukin-1 and tumour necrosis factor in non-Hodgkin's lymphoma patients

Jhaver, Kanchan; De, Asit K.; Advani, Suresh H.; Nadkarni, Jayshree J.

doi:10.1007/bf01741346

Cited by 5 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ability of monocytes to secrete these cytokines is a relevant assessment of their functional capacity. [23][24] The monocyte/macrophage function was studied with respect to their ability to produce IL-1, IL-6 and TNF in CLL patients, spontaneously and in presence of lipopolysaccheride, in comparison with normal population. Significantly decreased levels of IL The investigations presented here clearly indicate that the monocyte function is impaired and deficient in CLL patients.…”

Section: Discussionmentioning

confidence: 99%

Dysregulated Cytokine Production by Monocytes from Chronic Lymphocytic Leukemia Patients

Anand¹,

Chodda²,

Parikh³

et al. 1998

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

The serum levels of proinflammatory cytokines (Tumor Necrosis Factor, Interleukin-1, Interleukin-6) in B-cell Chronic Lymphocytic Leukemia (CLL), and secretion of these cytokines by monocytes from CLL patients has been studied in 27 CLL patients and 20 normal subjects under unstimulated and stimulated conditions. It has been observed that monocyte function is impaired and deficient in CLL patients. The cytokine secretion though decreased in unstimulated cultures, was found to reach normal levels as far as IL-6 and TNF are concerned, indicating a possible role of an in vivo suppressive factor. The observed defect in cytokine production may have an important implication for the immune system of the patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Dysregulated Cytokine Production by Monocytes from Chronic Lymphocytic Leukemia Patients

Anand¹,

Chodda²,

Parikh³

et al. 1998

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

show abstract

“…On the other hand, TNF elevated levels have also been found in the plasma of patients with various histological types of tumours (Balkwill et al, 1987), indicating that either various tumour cell types can produce this cytokine or that its production may rather reflect the immune response of the host against tumour. Others have reported that circulating TNF found in low-grade B-cell malignancies could be produced by peripheral blood monocytes (Adami et al, 1994;Jhaver et al, 1991). Interestingly, tumour-infiltrating lymphocytes obtained from lymphoma specimens have also been shown to preferentially secrete high levels of TNF upon autologous tumour cells stimulation (Schwartzentruber et al, 1993).…”

Section: Discussionmentioning

confidence: 99%

ELEVATED CIRCULATING LEVELS OF TNFα AND ITS p55 SOLUBLE RECEPTOR ARE ASSOCIATED WITH AN ADVERSE PROGNOSIS IN LYMPHOMA PATIENTS

Bienvenu²,

et al. 1996

View full text Add to dashboard Cite

In 88 newly diagnosed lymphoma patients, tumour necrosis factor alpha (TNFalpha) and soluble TNF type I receptor (p55-R-TNF) were prospectively determined in plasma by immunoradiometric assay (IRMA) and ELISA methods respectively. These 88 patients included 19 with centrocyto-centroblastic lymphoma, 13 patients with other low-grade lymphoma, and 56 with high-grade lymphoma. Median TNFalpha plasma values were 20 pg/ml (range 5-380 pg/ml) in patients versus 7 pg/ml (range 4-9 pg/ml) in 20 healthy control subjects. Presence of TNFalpha level > or = 20 pg/ml was significantly associated with elevated LDH level (P<0.0001), serum beta2-microglobulin level > or = 3 mg/l (P<0.0001), haemoglobin < or = 12 g/dl (P=0.0001), Ann Arbor stage III or IV disease (P<0.005), and with bulky tumour (P=0.01). High level of TNFalpha was also associated with B symptoms (P<0.005), poor performance status (P<0.05), and serum albumin < or = 35 g/l (P<0.05). Levels of p55-R-TNF were also markedly elevated in these lymphoma patients (median of 3.5 ng/ml, range 0.8-18.8 ng/ml) versus 1.45 ng/ml in control subjects (range 1.1-2.3 ng/ml). Level of p55-R-TNF > or = 3.5 ng/ml was significantly associated with poor performance status (P<0.0001), B symptoms (P<0.0001), beta2-microglobulin levels > or = 3 mg/l (P<0.0001), serum albumin < or = 35 g/l (P=0.0001), C-reactive protein > 6 mg/l (P=0.0003), elevated (>20 pg/ml) IL-6 level (P<0.005), haemoglobin < or = 12 g/dl (P<0.005), and bulky tumour (P<0.001). In the whole group of 88 patients, both high TNFalpha and p55-R-TNF levels strongly predicted short progression-free survival (P<0.005 for both variables) and overall survival (P<0.001 and P<0.001 respectively). In multivariate analyses the elevation of p55-R-TNF retained a higher significance over the other variables and therefore improved the predictive value of the International Prognostic Index. This study suggests that elevated TNF gamma and p55-R-TNF levels have high correlation with other adverse prognostic factors in lymphoma patients and may predict a poor outcome.

show abstract

“…With the introduction of the purine analogs on the treatment schedules of LG-NHL (11)(12)(13)(14)(15)(16) the number of biological studies of these slow proliferative activity diseases is growing. Tumor necrosis factor alpha (TNF-a) and soluble CD23 (sCD23) (the CD23 antigen is a 45-kd transmembrane glycoprotein that binds immunoglobulin E with low affinity; the spontaneous proteolytic cleavage of CD23 results in the generation of soluble fragments) concentrations have been reported to significantly predict treatment outcome of disease in B-cell chronic lymphocytic leukemia and in a few patients with LG-NHL (17)(18)(19)(20).…”

Section: Itroductionmentioning

confidence: 99%

Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low‐grade non‐Hodgkin's lymphoma

Zinzani

Baccini

Zaccaria

et al. 1996

European J of Haematology

View full text Add to dashboard Cite

In the last few years the research for new biological features in low‐grade non‐Hodgkin's lymphoma has provided important results. Several biological parameters are under evaluation and, in particular, cytokines and soluble receptors levels are showing their importance as prognostic parameters. In the present study, serum levels of tumor necrosis factor alpha (TNF‐α) and soluble CD23 (sCD23) were measured at the time of diagnosis and after induction polychemotherapy in 40 patients with newly diagnosed low‐grade non‐Hodgkin's lymphoma (LG‐NHL). The treaments were CIOP (cyclophosphamide, idarubicin, vincristine, prednisone) regimen for 28 patients and FMP (fludarabine, mitoxantrone, prednisone) scheme for 12 patients. Pretreatment levels of TNF‐α were highly elevated in patients with LG‐NHL compared with healthy controls (p=0.005) and were significantly correlated with the Ann Arbor stage (p=0.001). sCD23 was detected in 35 patients at diagnosis and were markedly increased in LG‐NHL patients when compared to healthy controls (p=0.005); patients with advanced stage presented higher values than those with early stage disease (p=0.002). All the complete responders (20/40, 50%) showed a decrease of TNF‐α and sCD23 levels. By contrast, the combination of high levels of TNF‐α and sCD23 correspond to a group of non‐responders. Our results suggest that TNF‐α and sCD23 are specific prognostic parameters for LG‐NHL, and that they could be used as tumor markers within a potential biological prognostic index.

show abstract

Production of interleukin-1 and tumour necrosis factor in non-Hodgkin's lymphoma patients

Cited by 5 publications

References 25 publications

Dysregulated Cytokine Production by Monocytes from Chronic Lymphocytic Leukemia Patients

Dysregulated Cytokine Production by Monocytes from Chronic Lymphocytic Leukemia Patients

ELEVATED CIRCULATING LEVELS OF TNFα AND ITS p55 SOLUBLE RECEPTOR ARE ASSOCIATED WITH AN ADVERSE PROGNOSIS IN LYMPHOMA PATIENTS

Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low‐grade non‐Hodgkin's lymphoma

Contact Info

Product

Resources

About